NASDAQ:OSUR - Nasdaq - US68554V1089 - Common Stock - Currency: USD
2.99
+0.07 (+2.4%)
The current stock price of OSUR is 2.99 USD. In the past month the price decreased by -15.54%. In the past year, price decreased by -43.37%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ALC | ALCON INC | 30.34 | 46.24B | ||
COO | COOPER COS INC/THE | 21.09 | 15.90B | ||
ALGN | ALIGN TECHNOLOGY INC | 18.35 | 12.55B | ||
SOLV | SOLVENTUM CORP | 9.9 | 11.46B | ||
LNTH | LANTHEUS HOLDINGS INC | 14.94 | 6.94B | ||
MMSI | MERIT MEDICAL SYSTEMS INC | 26.12 | 5.37B | ||
BLCO | BAUSCH + LOMB CORP | 19.45 | 4.26B | ||
ICUI | ICU MEDICAL INC | 22.29 | 3.41B | ||
HAE | HAEMONETICS CORP/MASS | 13.52 | 2.87B | ||
XRAY | DENTSPLY SIRONA INC | 7.68 | 2.56B | ||
UFPT | UFP TECHNOLOGIES INC | 27.77 | 1.62B | ||
NEOG | NEOGEN CORP | 11.55 | 952.81M |
OraSure Technologies, Inc. engages in the development, manufacture, and distribution of point of care diagnostic tests and molecular collection devices designed to detect or diagnose critical medical conditions. The company is headquartered in Bethlehem, Pennsylvania and currently employs 501 full-time employees. The firm's product portfolio is divided into diagnostics products and sample management solutions. Its business consists of the development, manufacture, marketing and sale of diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products including immunoassays and other in vitro diagnostic tests that are used on other specimen types. Its diagnostic products include tests for diseases including COVID-19, HIV and Hepatitis C that are performed on a rapid basis at the point of care, and tests for drugs of abuse that are processed in a laboratory. Its business also includes molecular sample management solutions and services that are used by clinical laboratories, direct-to-consumer laboratories, researchers, pharmaceutical companies, and animal health service and product providers.
ORASURE TECHNOLOGIES INC
220 E First St
Bethlehem PENNSYLVANIA 18015 US
CEO: Stephen S. Tang
Employees: 638
Company Website: https://www.orasure.com/
Investor Relations: https://orasure.gcs-web.com/
Phone: 15036416115
The current stock price of OSUR is 2.99 USD. The price increased by 2.4% in the last trading session.
The exchange symbol of ORASURE TECHNOLOGIES INC is OSUR and it is listed on the Nasdaq exchange.
OSUR stock is listed on the Nasdaq exchange.
10 analysts have analysed OSUR and the average price target is 5.1 USD. This implies a price increase of 70.57% is expected in the next year compared to the current price of 2.99. Check the ORASURE TECHNOLOGIES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ORASURE TECHNOLOGIES INC (OSUR) has a market capitalization of 231.70M USD. This makes OSUR a Micro Cap stock.
ORASURE TECHNOLOGIES INC (OSUR) currently has 638 employees.
ORASURE TECHNOLOGIES INC (OSUR) has a support level at 2.92 and a resistance level at 3.34. Check the full technical report for a detailed analysis of OSUR support and resistance levels.
The Revenue of ORASURE TECHNOLOGIES INC (OSUR) is expected to decline by -28.01% in the next year. Check the estimates tab for more information on the OSUR EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
OSUR does not pay a dividend.
ORASURE TECHNOLOGIES INC (OSUR) will report earnings on 2025-05-07, after the market close.
ORASURE TECHNOLOGIES INC (OSUR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.26).
The outstanding short interest for ORASURE TECHNOLOGIES INC (OSUR) is 3.44% of its float. Check the ownership tab for more information on the OSUR short interest.
ChartMill assigns a fundamental rating of 3 / 10 to OSUR. While OSUR has a great health rating, there are worries on its profitability.
Over the last trailing twelve months OSUR reported a non-GAAP Earnings per Share(EPS) of -0.26. The EPS decreased by -129.55% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -4.06% | ||
ROE | -4.75% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 78% to OSUR. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of -143.23% and a revenue growth -28.01% for OSUR